バイオ医薬品の世界市場

◆英語タイトル:Global Biopharmaceuticals Market
◆商品コード:MDR807SP08UE
◆発行会社(調査会社):Mordor Intelligence
◆発行日:2018年4月
◆ページ数:215
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,250 ⇒換算¥467,500見積依頼/購入/質問フォーム
Corporate(全社内共有可)USD8,750 ⇒換算¥962,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

The global biopharmaceuticals market is estimated to reach USD 341.16 billion in 2023. The market is expected to register a CAGR of 8.5% during the forecast period (2018 – 2023). North America dominates the market due to rapid technological advancements.

Increasing Acceptance for Biopharmaceuticals and Significant Market Demand
Opportunities in biopharmaceuticals have been increasing over the past decade. The efficacy and the safety of the drugs are some of the key product features that drive the market’s growth. There have been biopharmaceutical products that are improving the quality of life and reducing the death rates in patients with HIV/AIDs, cancer, cystic fibrosis, rheumatoid arthritis. Biopharmaceuticals have reduced the number of deaths caused due to cancer and HIV/AIDS in the last decade. The efficacy of the drugs and their safety has increased the acceptance for biopharmaceuticals.

High-end Manufacturing Requirements
Unlike conventional pharmaceuticals, biopharmaceuticals are manufactured using living biological systems. Due to this, biopharmaceutical manufacturing requires specialized equipment and devices such as incubators that can support these biological systems. The cost of these devices and equipment is high as compared to regular manufacturing equipment. Along with this, most biopharmaceuticals require custom built manufacturing equipment and highly specialized personnel to operate them. Due to these high-end manufacturing requirements, the resources and time required to setup a biopharmaceutical manufacturing facility is very high, which makes scaling really tough. So, these factors are acting as a restraint for the BIOPHARMACEUTICALS market.

North America to Dominate the Market
The biopharmaceuticals market is segmented by type of treatment and geography. By geography, it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America.

North America dominates the biopharmaceuticals market due to rapid technological advancements and high investment & funding to support development of biopharmaceuticals. Asia-Pacific is also expected to propel the biopharmaceuticals market owing to factors, such as increasing accessibility to healthcare facilities in the region and increasing economic growth.

Key Developments In The Market
January 2018: GE Healthcare’s Flex Factory single-use bio manufacturing platform has been selected by Clover Biopharmaceuticals, a Chinese developer of biologics, for its new facility located in Changxing, Zhejiang.
January 2018: Sandoz, a Novartis division and the global leader in biosimilars, announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.

Major key players: AbbVie, Amgen, Bristol – Myers Squibb, Eli Lily & Co., Johnson & Johnson, Merck & Co. Inc, GlaxoSmithKline PLC, Roche, Pfizer and Novartis AG, among others.

【レポートの目次】

1. INTRODUCTION
1.1 MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. KEY INFERENCES

5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER’S FIVE FORCES
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY

6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 INCREASING ACCEPTANCE FOR BIOPHARMACEUTICALS
6.1.2 HUGE MARKET DEMAND
6.2 MARKET RESTRAINTS
6.2.1 HIGH-END MANUFACTURING REQUIREMENTS
6.3 OPPORTUNITIES
6.4 KEY CHALLENGES

7. MARKET SEGMENTATION
7.1 GLOBAL BIOPHARMACEUTICAL MARKET, BY PRODUCT/TYPE
7.2 MONOCLONAL ANTIBODIES
7.2.1 ANTI-CANCER MONOCLONAL ANTIBODIES
7.2.2 ANTI-INFLAMMATORY MONOCLONAL ANTIBODIES
7.2.3 OTHER MONOCLONAL ANTIBODIES
7.3 RECOMBINANT GROWTH FACTOR
7.3.1 ERYTHROPOIETIN
7.3.2 GRANULOCYTE COLONY STIMULATING FACTOR
7.4 PURIFIED PROTEIN
7.4.1 LEUKEMIA INHIBITORY FACTOR (LIF)
7.4.2 P53 PROTEIN
7.4.3 P38 PROTEIN
7.5 RECOMBINANT PROTEIN
7.5.1 SERUM ALBUMIN
7.5.2 AMYLOID PROTEIN
7.5.3 DEFENSIN
7.5.4 CYCLASE
7.5.5 CASPASE
7.5.6 CATHEPSIN
7.6 RECOMBINANT HORMONE
7.6.1 RECOMBINANT HUMAN GROWTH HORMONE (HGH)
7.6.2 INSULIN
7.7 SYNTHETIC IMMUNOMODULATOR
7.8 VACCINE
7.8.1 RECOMBINANT VACCINE
7.8.1.1 CANCER VACCINE
7.8.1.2 MALARIA VACCINE
7.8.1.3 EBOLA VACCINE
7.8.1.4 HEPATITIS-B VACCINE
7.8.1.5 TETANUS VACCINE
7.8.1.6 DIPTHERIA VACCINE
7.8.1.7 CHOLERA VACCINE
7.8.2 CONVENTIONAL VACCINE
7.8.2.1 POLIO VACCINE
7.8.2.2 POX VACCINE
7.9 RECOMBINANT ENZYME
7.9.1 ENTEROKINASE
7.9.2 TRANSFERRIN
7.10 OTHERS
7.10.1 BLOOD FACTORS
7.10.2 OTHERS
7.11 BY GEOGRAPHY
7.11.1 NORTH AMERICA
7.11.1.1 US
7.11.1.2 CANADA
7.11.1.3 MEXICO
7.11.2 EUROPE
7.11.2.1 FRANCE
7.11.2.2 UK
7.11.2.3 GERMANY
7.11.2.4 ITALY
7.11.2.5 SPAIN
7.11.2.6 REST OF EUROPE
7.11.3 ASIA-PACIFIC
7.11.3.1 INDIA
7.11.3.2 CHINA
7.11.3.3 JAPAN
7.11.3.4 AUSTRALIA
7.11.3.5 SOUTH KOREA
7.11.3.6 REST OF APAC
7.11.4 MIDDLE EAST & AFRICA
7.11.4.1 GCC
7.11.4.2 SOUTH AFRICA
7.11.4.3 REST OF MIDDLE EAST & AFRICA
7.11.5 SOUTH AMERICA
7.11.5.1 BRAZIL
7.11.5.2 ARGENTINA
7.11.5.3 REST OF SOUTH AMERICA

8. COMPETITIVE LANDSCAPE
8.1 MERGERS AND ACQUISITIONS
8.2 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS
8.3 NEW PRODUCT LAUNCHES

9. KEY PLAYERS
9.1 ABBVIE
9.2 AMGEN INC.
9.3 BRISTOL – MYERS SQUIBB
9.4 ELI LILY & CO.
9.5 JOHNSON & JOHNSON
9.6 MERCK & CO. INC.
9.7 NOVARTIS AG
9.8 PFIZER
9.9 GLAXOSMITHKLINE PLC
9.10 ROCHE HOLDING
9.11 OTHERS

10. FUTURE OF THE MARKET



★調査レポート[バイオ医薬品の世界市場] (コード:MDR807SP08UE)販売に関する免責事項を必ずご確認ください。
★調査レポート[バイオ医薬品の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆